406 related articles for article (PubMed ID: 35842249)
21. [THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].
Murakami Y; Sugiyama A; Ideguchi H; Murakami Y; Amimoto Y; Nishie H; Odajima H
Arerugi; 2020; 69(3):213-217. PubMed ID: 32435023
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-31 and Pruritic Skin.
Furue M; Furue M
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33924978
[TBL] [Abstract][Full Text] [Related]
23. Prurigo Nodularis: Review and Emerging Treatments.
Leis M; Fleming P; Lynde CW
Skin Therapy Lett; 2021 May; 26(3):5-8. PubMed ID: 34077168
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Kaneda N
Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
[TBL] [Abstract][Full Text] [Related]
25. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
Ruzicka T; Hanifin JM; Furue M; Pulka G; Mlynarczyk I; Wollenberg A; Galus R; Etoh T; Mihara R; Yoshida H; Stewart J; Kabashima K;
N Engl J Med; 2017 Mar; 376(9):826-835. PubMed ID: 28249150
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
Nakashima C; Otsuka A; Kabashima K
Exp Dermatol; 2018 Apr; 27(4):327-331. PubMed ID: 29524262
[TBL] [Abstract][Full Text] [Related]
27. Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
Olbrich H; Sadik CD; Ludwig RJ; Thaçi D; Boch K
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189381
[TBL] [Abstract][Full Text] [Related]
28. Nemolizumab for atopic dermatitis.
Labib A; Vander Does A; Yosipovitch G
Drugs Today (Barc); 2022 Apr; 58(4):159-173. PubMed ID: 35412530
[TBL] [Abstract][Full Text] [Related]
29. Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
Frølunde AS; Wiis MAK; Ben Abdallah H; Elsgaard S; Danielsen AK; Deleuran M; Vestergaard C
Dermatology; 2022; 238(5):950-960. PubMed ID: 35417906
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.
Napolitano M; Fabbrocini G; Scalvenzi M; Nisticò SP; Dastoli S; Patruno C
Dermatitis; 2020; 31(1):81-84. PubMed ID: 31517666
[TBL] [Abstract][Full Text] [Related]
31. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
Kabashima K; Furue M; Hanifin JM; Pulka G; Wollenberg A; Galus R; Etoh T; Mihara R; Nakano M; Ruzicka T
J Allergy Clin Immunol; 2018 Oct; 142(4):1121-1130.e7. PubMed ID: 29753033
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomised, double-blind, placebo-controlled, phase II/III clinical study in patients aged ≥13 years.
Yokozeki H; Murota H; Matsumura T; Komazaki H;
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38629497
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues.
Nemmer JM; Kuchner M; Datsi A; Oláh P; Julia V; Raap U; Homey B
Front Med (Lausanne); 2021; 8():639097. PubMed ID: 33644104
[TBL] [Abstract][Full Text] [Related]
34. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
35. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
[TBL] [Abstract][Full Text] [Related]
36. IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.
Roh YS; Choi J; Sutaria N; Belzberg M; Kwatra MM; Kwatra SG
Drugs; 2021 Jun; 81(8):895-905. PubMed ID: 33881741
[TBL] [Abstract][Full Text] [Related]
37. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262
[TBL] [Abstract][Full Text] [Related]
38. Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis.
Conrad C; Schlapbach C
J Allergy Clin Immunol; 2024 Jan; 153(1):93-94. PubMed ID: 37951309
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
40. Reversal of the disease signature in prurigo nodularis by blocking the itch cytokine.
Sonkoly E
J Allergy Clin Immunol; 2022 Apr; 149(4):1213-1215. PubMed ID: 35189125
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]